Inhibition of 4T1 mammary tumor growth in BALB/c mice by subcutaneous and intraperitoneal injection of a 4T1 whole cell vaccine containing IL-2 and GM-CSF as adjuvants
Tumor Models and Assays Abstract
? April 3, 2017, 8:00 - 12:00 PM ? Section 28
Presenter/AuthorsJonathan F. Head1, Jeffrey T. Phillips1, Xianpeng Jiang1, Robert L. Elliott2. 1OncBioMune Pharmaceuticals, Baton Rouge, LA; 2SAB Breast Foundation, Baton Rouge, LA Disclosures J.F. Head: ; Oncbiomune Pharmaceuticals. J.T. Phillips: ; Oncbiomune Pharmaceuticals. X. Jiang: ; Oncbiomune Pharmaceuticals. R.L. Elliott: ; Oncbiomune Pharmaceuticals.AbstractDeveloping animal tumor models for human cancer vaccines creates a tool to investigate the mechanism of action, variations in formulation, dosing schedules, and combinations with other forms of cancer therapy. In this study we developed a mouse whole cell mammary cancer vaccine model with both subcutaneous and intraperitoneal injection of the vaccine. The vaccine, containing 4T1 mouse mammary cancer cells (1,000,000 cells), IL-2 (0.2 µg) and GM-CSF (0.1 µg) in a total volume of 150 µl, was injected either subcutaneously into the backs of BALB/c mice or intraperitoneally. There were six injections of the vaccine (weeks 1, 2, 3, 7, 11, 15) and one week after the last injection 100,000 4T1 cells from cell culture in a volume of 100 µl were injected into the scapular region of the mice. At 22 days post 4T1 tumor transplantation there was a 37% inhibition of the growth of the 4T1 tumor in the mice receiving the subcutaneous injection of the vaccine and a 42% inhibition of the growth of the 4T1 tumor in the mice receiving the intraperitoneal injection of the vaccine. The inhibition of 4T1 mammary tumor growth in this mouse model with subcutaneous injection of a whole cell vaccine gives further support for the previously reported efficacy in a Phase 1/2 clinical trial of our therapeutic breast cancer vaccine containing autologous and allogeneic breast cancer cells in the adjuvant setting. The inhibition of 4T1 tumor growth with intraperitoneal injection suggests a delivery method that may be applicable to ovarian cancer and cancer patients with malignant ascites.
http://www.abstractsonline.com/pp8/#!/4292/presentation/3310
April 3, 2017, 8:00 AM
? PO.IM01.05. Tumor Models and Assays
Section 28
8:00 - 12:00 PM 1664 / 12 - Inhibition of 4T1 mammary tumor growth in BALB/c mice by subcutaneous and intraperitoneal injection of a 4T1 whole cell vaccine containing IL-2 and GM-CSF as adjuvants
Jonathan F. Head1, Jeffrey T. Phillips1, Xianpeng Jiang1, Robert L. Elliott2. 1OncBioMune Pharmaceuticals, Baton Rouge, LA; 2SAB Breast Foundation, Baton Rouge, LA
================================================
By my chart on the daily, being back inside the Bollinger now, I think we're looking pretty good. And I think we'll be getting some more attention where it counts too.
Looking pretty good going into April. May just start cutting resistance like a hot knife through butter.
Tumor Models and Assays Abstract
? April 3, 2017, 8:00 - 12:00 PM ? Section 28
Presenter/AuthorsJonathan F. Head1, Jeffrey T. Phillips1, Xianpeng Jiang1, Robert L. Elliott2. 1OncBioMune Pharmaceuticals, Baton Rouge, LA; 2SAB Breast Foundation, Baton Rouge, LA Disclosures J.F. Head: ; Oncbiomune Pharmaceuticals. J.T. Phillips: ; Oncbiomune Pharmaceuticals. X. Jiang: ; Oncbiomune Pharmaceuticals. R.L. Elliott: ; Oncbiomune Pharmaceuticals.AbstractDeveloping animal tumor models for human cancer vaccines creates a tool to investigate the mechanism of action, variations in formulation, dosing schedules, and combinations with other forms of cancer therapy. In this study we developed a mouse whole cell mammary cancer vaccine model with both subcutaneous and intraperitoneal injection of the vaccine. The vaccine, containing 4T1 mouse mammary cancer cells (1,000,000 cells), IL-2 (0.2 µg) and GM-CSF (0.1 µg) in a total volume of 150 µl, was injected either subcutaneously into the backs of BALB/c mice or intraperitoneally. There were six injections of the vaccine (weeks 1, 2, 3, 7, 11, 15) and one week after the last injection 100,000 4T1 cells from cell culture in a volume of 100 µl were injected into the scapular region of the mice. At 22 days post 4T1 tumor transplantation there was a 37% inhibition of the growth of the 4T1 tumor in the mice receiving the subcutaneous injection of the vaccine and a 42% inhibition of the growth of the 4T1 tumor in the mice receiving the intraperitoneal injection of the vaccine. The inhibition of 4T1 mammary tumor growth in this mouse model with subcutaneous injection of a whole cell vaccine gives further support for the previously reported efficacy in a Phase 1/2 clinical trial of our therapeutic breast cancer vaccine containing autologous and allogeneic breast cancer cells in the adjuvant setting. The inhibition of 4T1 tumor growth with intraperitoneal injection suggests a delivery method that may be applicable to ovarian cancer and cancer patients with malignant ascites.
http://www.abstractsonline.com/pp8/#!/4292/presentation/3310
April 3, 2017, 8:00 AM
? PO.IM01.05. Tumor Models and Assays
Section 28
8:00 - 12:00 PM 1664 / 12 - Inhibition of 4T1 mammary tumor growth in BALB/c mice by subcutaneous and intraperitoneal injection of a 4T1 whole cell vaccine containing IL-2 and GM-CSF as adjuvants
Jonathan F. Head1, Jeffrey T. Phillips1, Xianpeng Jiang1, Robert L. Elliott2. 1OncBioMune Pharmaceuticals, Baton Rouge, LA; 2SAB Breast Foundation, Baton Rouge, LA
================================================
By my chart on the daily, being back inside the Bollinger now, I think we're looking pretty good. And I think we'll be getting some more attention where it counts too.
Looking pretty good going into April. May just start cutting resistance like a hot knife through butter.
